• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 13, 2018

View Archived Issues

The Tao of Tau: Lilly licenses AC Immune's small-molecule program in potential $1.9B pact

DUBLIN – AC Immune SA's distinctive approach to addressing drug targets associated with Alzheimer's disease has secured more big pharma validation, in the form of a mammoth license agreement with Eli Lilly and Co. covering its preclinical portfolio of small-molecule tau aggregation inhibitors. Lausanne, Switzerland-based AC Immune is banking CHF80 million (US$80.6 million) up front, another CHF50 million from a loan-to-equity instrument and an expected CHF60 million in near-term milestones. It could also earn up to CHF1.7 billion more in development, regulatory and commercial milestones, as well as tiered low double-digit royalties on product sales. Read More

Shares of Chinese drugmakers plunge amid moves to cut prices of generics

HONG KONG – Chinese drugmakers' stocks hit their worst slump since 2008 last week on reports of a government pilot program aimed at lowering generic drug prices. Read More

Fool's GOLD: Neurocrine puts Tourette to rest after phase IIb Ingrezza failure

A somber Kevin Gorman was brutally honest with analysts Wednesday, advising them to remove Tourette syndrome (TS) from their Neurocrine Biosciences Inc. model after Ingrezza (valbenazine) missed the primary endpoint of change from baseline to week 12 in Yale Global Tic Severity Scale (YGTSS) score among children and adolescents with moderate to severe symptoms enrolled in the phase IIb T-Force GOLD study. Read More

Indian biosimilars industry at cusp of growth: report

NEW DELHI – With record domestic approvals, active engagement in semi-regulated markets and a growing footprint in regulated markets, the Indian biosimilars industry is poised to hit the $40 billion mark by 2030, according to a new industry analysis report. Read More

Aeglea readies pivotal test of therapy for rare metabolic disorder

A single pivotal phase III trial of an enzyme engineered to treat a rare urea cycle disorder, arginase 1 deficiency (ARG1-D), could potentially support U.S. and European approvals of the therapy, according to Aeglea Biotherapeutics Inc. The Austin, Texas-based biotech expects to start dosing a small group of patients with the enzyme, its lead candidate pegzilarginase, during the second quarter of 2019 and to make top-line data available in the first quarter of 2021. Read More

China's Bio-Thera kicks off phase I trial for CD20 Mab, cites best-in-class potential

HONG KONG – China's Bio-Thera Solutions Ltd. has launched the phase I trial of BAT-4306F, an antibody-dependent cellular cytotoxicity (ADCC)-enhanced monoclonal antibody (MAb) that seeks to treat relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma patients. Read More

Financings

Checkmate Pharmaceuticals Inc., of Cambridge, Mass., said it completed a $22 million financing led by a new investor, Decheng Capital. The proceeds will support ongoing clinical development of its lead product, CMP-001, in advanced melanoma and non-small-cell lung cancer refractory to prior anti-PD-1 therapy, along with expansion into additional solid tumor types. Read More

Other news to note

Q Biomed Inc., of New York, said it will work with Menlo Park, Calif.-based SRI International to provide formulation development, preclinical development and early clinical manufacturing of QBM-001, the company's preclinical program for autistic spectrum disorder drug development program for nonverbal or minimally verbal autistic children. Read More

Regulatory front

In what could be the next step toward a 21st Century Cures approach to health care spending, Senate Health, Education, Labor and Pensions (HELP) Committee Chair Lamar Alexander (R-Tenn.) is tapping on think tanks, economists, state officials, patients and other stakeholders across the health care enterprise for suggestions on what Congress can do to rein in U.S. costs.  Read More

Appointments and advancements

Matinas Biopharma Holdings Inc., of Bedminster, N.J., appointed Christie M. Ballantyne, John J.P. Kastelein and Kevin C. Maki to its scientific advisory board. Read More

Clinical data for Dec. 12, 2018

Read More

Regulatory actions for Dec. 12, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe